PureTech
Developing and commercializing highly differentiated medicines for devastating diseases.
Launch date
Employees
Market cap
€421m
Enterprise valuation
(€19m) (Public information from Sep 2024)
Share price
£1.43512 PRTC.L
Boston Massachusetts (HQ)
Notable known LPs: JDRF
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 8.3m | 10.0m | 2.1m | <1m | 28.4m | 35.2m | 22.8m |
% growth | (4 %) | 20 % | (79 %) | (64 %) | 3691 % | 24 % | (35 %) |
EBITDA | (145m) | (215m) | (203m) | (132m) | (130m) | (137m) | (140m) |
% EBITDA margin | (1735 %) | (2153 %) | (9699 %) | (17641 %) | (457 %) | (389 %) | (613 %) |
Profit | 6.0m | (60.6m) | (50.4m) | (65.7m) | (128m) | (115m) | (147m) |
% profit margin | 72 % | (607 %) | (2409 %) | (8760 %) | (449 %) | (328 %) | (647 %) |
EV / revenue | 147.7x | 72.6x | 267.9x | 607.3x | 3.7x | 2.0x | 2.9x |
EV / EBITDA | -8.5x | -3.4x | -2.8x | -3.4x | -0.8x | -0.5x | -0.5x |
R&D budget | 61.2m | 81.5m | 116m | 73.7m | - | - | - |
R&D % of revenue | 734 % | 817 % | 5556 % | 9831 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
N/A | $50.0m | Late VC | |
N/A | N/A | IPO | |
* | $11.4m | Grant | |
Total Funding | €55.8m |
Related Content
Recent News about PureTech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
Investments by PureTech
EditACQUISITION by Bristol-Myers Squibb Dec 2023
exited
ACQUISITION by PureTech Jun 2021